Drug Profile
Research programme: small molecule therapeutics - Shanghai De Novo Pharmatech
Alternative Names: DN 1403; DN 1406; DN 1507; DN 1508; DN 4; DN-014; DN-015; DN1609; DN1611; QF 036; SC 110237Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Shanghai De Novo Pharmatech
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Cancer; Diabetes mellitus; Viral infections
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Cancer in China
- 28 Dec 2020 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in China (PO)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in China